BridgeBio plans U.S. launches of BBP-418, encaleret by 2027
BridgeBio Pharma said it will launch BBP-418, encaleret and infigratinib in the U.S. by 2027, while analysts including Leerink and Stifel trimmed BBIO price targets.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.